Harrow Expands Access to VEVYE® for Klarity-C Patients at $59 Per Bottle
Harrow (Nasdaq: HROW), a leading eyecare pharmaceutical company in North America, has announced the expansion of its VEVYE® Access for All (VAFA) program to include current users of Klarity-C Drops®, a compounded cyclosporine 0.1% product from its compounding subsidiary, ImprimisRx®.
Effective immediately, over 25,000 patients across the U.S. currently prescribed Klarity-C will be eligible to switch to VEVYE® (cyclosporine ophthalmic solution) 0.1%—an FDA-approved treatment for the signs and symptoms of dry eye disease—at a cost of just $59 per bottle, including refills.
Since its launch on March 17, 2025, the VAFA program has aimed to simplify access to dry eye therapy by removing common barriers such as prior authorizations and insurance delays. The program offers benefits including:
- Free home delivery
- A no-questions-asked, money-back guarantee
- Flexibility to use insurance or access affordable cash pricing
To facilitate the transition, Klarity-C prescribers can use a streamlined prescription authorization platform to transfer scripts to PhilRx, a process that typically takes under five minutes.
Leadership and Clinical Reactions
“We’re proud to make VEVYE more accessible and affordable for Klarity-C patients,” said Mark L. Baum, CEO of Harrow. “The success of the VEVYE Access for All program lies in its simplicity—cutting patient costs and removing access burdens like prior authorizations. For patients, it means getting what their doctor prescribes at an affordable price. For providers, it’s a no-brainer.”
Ophthalmologist Dr. Alice Epitropoulos, Co-founder of the Eye Center of Columbus, welcomed the news: “Pharmaceutical companies often talk about removing access barriers, but Harrow actually delivers. Klarity-C was a valuable option for my patients without adequate insurance coverage. Now, with VEVYE offered at the same affordable price—without insurance headaches—it’s a game changer. This is real transparency and access that leads to better patient outcomes.”
Dr. Mitchell Jackson, founder and medical director of Jacksoneye, also praised the initiative: “We already know VEVYE delivers clinically. But how often does a pharmaceutical company reduce prices and pass the savings directly to patients, while removing insurance obstacles? Only Harrow. No prior authorizations, no step therapy, no surprise costs—just access to an excellent treatment. This is the model our healthcare system needs.”
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year.
